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Amyloid formation is cytotoxic and can activate the caspase cascade. Here, we monitor caspase-3-like activity as reduction of
ﬂuorescence resonance energy transfer (FRET) using the contstruct pFRET2-DEVD containing enhanced cyan ﬂuorescent protin
(EYFP) linked by the caspase-3 speciﬁc cleavage site residues DEVD. Beta-TC-6 cells were transfected, and the ﬂuoorescence
was measured at 440nm excitation and 535nm (EYFP) and 480nm (ECFP) emission wavelength. Cells were incubated with
recombinant pro lset Amyloid Polypeptide (rec prolAPP) or the processing metabolites of prolAPP; the N-terminal ﬂanking
peptidewithIAPP(recN+IAPP);IAPPwiththeC-terminalﬂankingpeptied(recIAPP+C)andlsletAmyloidPolypeptide(recIAPP)
. Peptides were added in solubilized from (50μM) or as performed amyloid-like ﬁbrils, or as a combination of these. FRET was
measured and incubation with a mixture of solubilized peptide and performed ﬁbrils resulted in loss of FRET and apoptosis was
determined to occure in cells incubated with recproIAPP (49%), recN+IAPP (46%), recIAPP (72%) and recIAPP+C (59%). These
results show that proIAPP and the processing intermediates reside the same cell toxic capacity as IAPP, and they can all have a
central role in the reduction of beta-cell number in type 2 diabetes.
Copyright © 2008 Johan F. Paulsson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
If proteins misfold or lose their native fold, they are usually
assisted to refold by molecular chaperons or they can be
removed from the system and be degraded [1]. However,
under certain circumstances this system seems to fail and
proteins escape degradation. Instead, they can aggregate into
ﬁbrilswithahighdegreeofbeta-pleatedsecondarystructure,
and if these ﬁbrils are stained by Congo red and exert green
birefringencewhenviewedinpolarisedlighttheyarereferred
to as amyloid [2–5]. Amyloid deposition is associated with
loss of organ function and cell death. Hitherto, at least 25
diﬀerent proteins have been characterised from systemic or
localised amyloid deposits in humans [4].
The amyloid formation process can be divided into
two phases. The ﬁrst is a nucleation forming process
where monomers of the amyloid peptide form preﬁbrillar
oligomeric species and this is referred to as the lag phase
[6, 7]. The second phase is the extension phase where rapid
elongation of amyloid ﬁbrils occurs which will reach a
plateau when most of the molecules are converted into the
ﬁbrillar form. A dramatic reduction of the lag phase will
occur if mature amyloid ﬁbrils of the same origin are added
andthisiscalledtheseedingeﬀect.Thereisgrowingevidence
that the cytotoxic species of the amyloid forming process
are early oligomers consisting of 15–40 monomers forming
a ring shaped structure [8–10]. These preﬁbrillar assemblies
areabletoincorporateandformporesincellularmembranes
causing cell leakage and inﬂux of cations which triggers the
apoptosis cascade. According to this, the amyloid ﬁbril itself
is a nontoxic end product of a cytotoxic aggregation process.
Amyloid deposits in the islets of Langerhans are a
pathological characteristic of type 2 diabetes, and the amy-
loid aggregates consist of islet amyloid polypeptide (IAPP)2 Experimental Diabetes Research
[11, 12]. IAPP is a product of the endocrine beta-cell and
as amyloid deposition occurs a large reduction of beta-cell
mass has been observed [13–15]. IAPP has also been shown
to form spherical structures with the capacity to incorporate
into lipid bilayers [16–18]. In vitro studies of diﬀerent cell
lines show that amyloid formation of IAPP is cytotoxic and
triggers the apoptotic pathway by activation of the caspase
cascade [19–21].
IAPP is expressed as a precursor molecule (proIAPP)
which is posttranslationally modiﬁed by the processing
enzymes prohormone convertase (PC) 2 and 1/3 [22–25].
In the secretory granule, proIAPP is cleaved between dibasic
residues at the N- and C-termini by PC2 and PC1/3,
respectively. We and others have previously shown in cell
lines that if aberrant processing of human proIAPP occurs,
intracellular amyloid-like aggregates arise with cell death as
ar e s u l t[ 26, 27]. Also intracellular amyloid-like aggregates
consistingofproIAPPhavebeendescribedinbothtransgenic
mice expressing human IAPP and in human beta-cells
[28]. Cells with intracellular amyloid-like material are also
positive for M30 cyto-death antibody which binds to an
early neoepitope that becomes accessible during caspase
activation.
Here,wedescribeanovelsystemformonitoringbeta-cell
apoptosis. The system uses two ﬂuorophores linked together
withacaspase3-likecleavagesite,andwhencleavageoccursa
reduction of ﬂuorescence resonance energy transfer (FRET)
can be measured as an indicator of apoptosis. Since mea-
surements of the same cells can be done repeatedly, real-time
monitoringofbeta-cellapoptosiscanbeperformed.Also,we
used the established assay to compare the apoptotic prop-
erties of recombinant proIAPP (recproIAPP) and proIAPP
processing intermediates, N-terminal ﬂanking peptide with
IAPP (recN+IAPP), IAPP with the C-terminal ﬂanking
peptide (recIAPP+C), and recombinant IAPP (recIAPP).
2. EXPERIMENTAL PROCEDURES
2.1. Celltransfection
Beta-TC-6(B-TC-6)cellsobtainedfromAmericanTypeCul-
ture Collection (Manassas, VA, USA) were cultured to 80%
conﬂuency in 10cm diameter Petri dishes (Falcon: Labora,
Stockholm, Sweden) in RPMI-1640 medium with 11mM D-
glucose containing 10% fetal bovine serum (FBS) (Sigma,
Stockholm, Sweden), 100IU/ml penicillin, 100μg/ml strep-
tomycin, 50μM β-mercaptoethanol. One hour prior to
transfection, medium was changed to RPMI-1640 medium
withoutserum.Atotalvolumeof175μLwith20μgpFRET2-
DEVD, 20μg pcDNA3, 10mM polyethyleneimine, and 5%
sucrose was added to 9mL of RPMI-1640 medium without
serum. After 6 hours of incubation, FBS was added to a
ﬁnalconcentrationof10%.After24hours,0.4mg/mLG-418
antibiotics was added to the medium for selection of stabile
B-TC-6 clones.
2.2. Assaybuffer
The following solutions were investigated for autoﬂuores-
cence: (1) Krebs-Ringer with hepes and glucose (KRHG)
(120mMNaCl,4.7mMKCl,2.5mMCaCl2,1.2mMMgSO 4,
0.5mM KH2PO4, pH 7.4 with 2mM D-glucose, 20mM
Hepes, and 200nM adenosine). (2) Hank’s balanced salt
solution (HBSS) (5.4mM KCl, 0.3mM NaHPO4,0 . 4 m M
KH2PO4, 4.2mM NaHCO3,1 . 3m MC a C l 2,0 . 5m MM g C l 2,
0.6mM MgSO4, 137mM NaCl, 5.6mM D-glucose, pH 7.4).
(3) RPMI-1640 medium without FBS (Sigma). (4) RPMI-
1640 medium with 10% FBS. (5) Dulbeccoc ¸s medium
without phenol red (Invitrogen, Carlsbad, Calif, USA).
(6) Schneiderc ¸s Drosophila medium without phenol red
(Invitrogen). (7) H20.
2.3. Real-timemonitoringofapoptosis
pFRET2-DEVD vector is driven by the insulin promoter
and can only be expressed in insulin producing cells. When
expressed, a product consisting of enhanced cyan ﬂuorescent
protein (ECFP) and enhanced yellow ﬂuorescent protein
(EYFP) linked by the amino acid residues DEVD will be
dispersed throughout cytoplasm. The sequence DEVD is
a speciﬁc substrate for caspase-3-like proteases and when
ECFP and EYFP are connected by the DEVD residues FRET
will occur. If the transfected B-TC-6 cells undergo apoptosis,
the DEVD is cleaved and the two ﬂuorophores will be
separated and a loss of FRET can be monitored as a decrease
of the 535nm/480nm ﬂuorescence ratio. The pFRET2-
DEVD vector has previously been characterised by K¨ ohler
et al. [29]. B-TC-6 cells with stable expression pFRET2-
DEVD were cultured for 48 hours in black 96 well plates
(Labsystems)to80%conﬂuencyandwashedonceinKRHG-
buﬀer prior to experimental procedures. Sample volume
was set to 100μL and both synthetic and recombinant
peptides were kept as stock solution of 5mM in dimethyl
sulfoxide (DMSO) and diluted to a ﬁnal concentration of
50μM with a ﬁnal DMSO concentration of 1%. Synthetic
human and rat IAPP were analysed in solubilised form
at ﬁnal concentrations of 25 and 50μM. Negative control
was 1% DMSO in KRHG-buﬀer and when seeded assays
were performed a ﬁnal concentration of 30nM synthetic
IAPP ﬁbrils was included in the negative control. Positive
control for apoptosis contained 2μM staurosporine and
1% DMSO in KRHG-buﬀer. Negative and positive controls
were included in each individual assay. Mature recombinant
amyloid-like ﬁbrils were washed in H2O and centrifuged
at 16.000g for 15 minutes and resuspended in KRHG-
buﬀer, sonicated and diluted to an estimated concentration
of 50μM.
Loss of FRET was measured in a Wallac 1420 multilabel
counter (Perkin Elmer, Turku, Finland) with WorkOut
software version 1.5 (Perkin Elmer). Excitation was set to
440nm, and emitted ﬂuorescence was measured at 535nm
(EYFP) and 480nm (ECFP). Data are presented as mean
ratio ±SEM of 535nm/480nm ratio. Each point represents
at least ﬁve individual measurements.
2.4. Confocalmicroscopy
B-TC-6 cells with stabile expression of pFRET2-DEVD and
untransfected B-TC-6 cells were cultured on 19mm coverJohan F. Paulsson et al. 3
Table 1: Forward and reverse primers for ampliﬁcation of IAPP fragments.
proIAPP forward 5 -GAT GAC ACC CAT TGA AAG TCA TCA GG-3 
proIAPP reverse 5 -CTA CTA AAG GGG CAA GTA ATT CAG TGG-3 
N-terminal+IAPP forward 5 -GAT GAC ACC CAT TGA AAG TCA TCA GG-3 
N-terminal+IAPP reverse 5 -CTA CTA GCC ATA TGT ATT GGA TCC CAC G-3 
IAPP forward 5 -GAT GAA ATG CAA CAC TGC CAC ATG-3 
IAPP reverse 5 -CTA CTA GCC ATA TGT ATT GGA TCC CAC G-3 
IAPP+C-terminal forward 5 -GAT GAA ATG CAA CAC TGC CAC ATG-3 
IAPP+C-terminal reverse 5 -CTA CTA AAG GGG CAA GTA ATT CAG TGG-3 
slips and rinsed in PBS (137mM NaCl, 2.7mM KCl, 4.3mM
Na2HPO4, and 1.4mM, KH2PO4) before ﬁxation in 2%
paraformaldehyde in PBS for 30 minutes. For visualisation,
cells were incubated with the nuclear stain TO-PRO-3
(Molecular probes, Eugene, Ore, USA) diluted 1 : 1000
in PBS for 15 minutes and then mounted with 50/50
glycerol/PBS. Cells were studied in a Nikon eclipse E600
microscope with a Nikon C1 confocal unit with argon
488nm and HeNe 633nm lasers (Nikon Kawasaki, Japan).
DigitalpicturesweretakenwithanEZ-C1digitalcameraand
software version 1.0 for Nikon confocal microscopy.
2.5. Productionofrecombinantpeptides
Human preproIAPP cloned into the pBluescript II vector
was used as template for generation of PCR ampliﬁed DNA
fragments corresponding to human proIAPP, N-terminal
ﬂankingpeptide+IAPP,IAPPandIAPP+C-terminalﬂanking
peptide. Forward and reverse primers used for this purpose
are described in Table 1. The ampliﬁed IAPP fragments
were blunt end ligated in expression vector pGEX 2TK (GE
healthcare, Uppsala, Sweden). Constructs were conﬁrmed
by sequencing to be in correct reading frame and with-
out mutations. The pGEX 2TK vector has glutathione S-
transferase (GST) in front of the multiple cloning site and
the peptide will be expressed as a GST fusion protein. Y1090
bacteria were transformed and cultured in Luria broth at
+37
◦C until OD A600 reached 0.8, and protein synthesis was
induced with 3mM isopropyl β-D-1 thiogalactopyranoside
(IPTG) (Fermentas, St Lenon Rot, Germany) for 3 hours
at +25
◦C. Bacteria were spun down and resuspended in
TEDG buﬀer (50mM TRIS-HCl pH 7.4, 1.5mM EDTA,
10% glycerol, 400mM NaCl) and sonicated three times
for 20 seconds. The bacteria lysate was centrifuged at
100.000g in a SW41 Ti rotor for 30 minutes at +4◦C,
and the supernatant was transferred to Sepharose-4B beads
(GE healthcare) and incubated 2 hours end over end at
+4◦C. Sepharose beads were spun down at 3000g for one
minute, and the lysate was decanted and the beads were
washed three times in NET-N buﬀer (50mM TRIS-HCl pH
7.4, 150mM NaCl, 5mM EDTA and 0.5% NONIDET-NP
40 (USB, Cleveland, Ohio, USA) followed by three times
wash in PBS. The GST-tag was cleaved oﬀ with thrombin
protease (GE healthcare) 20U/mg expected peptide in PBS
end over end overnight. Removal of the 27kDa GST-
tag resulted in rapid amyloid formation and aggregates
were collected. The amyloid-like ﬁbrils were washed in
ddH2O and solved in 50%/50% 1,1,1,3,3,3-hexaﬂuoro-2-
propanol (HFIP)/triﬂuoroacetic acid (TFA) for 24 hours.
Solubilised peptides were centrifuged at 16.000g for 15
minutes, and the supernatant was recovered. For assays with
IAPP recombinant peptides in complete monomeric form,
the supernatant was ﬁltered trough a Millex-FG syringe
ﬁlter 0.2μm for hydrophobic solvents. Samples were dried in
vacuum and redisolved in 100% DMSO. Peptide concentra-
tions for recproIAPP and recN+IAPP were determined using
A280 extinction coeﬃcient 1615 M−1 cm−1and for recIAPP
and recIAPP+C 3105 M−1 cm−1 in a nanodrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington,
Del, USA). Theoretical molecular masses were as follow:
recproIAPP 8358 Da, recN+IAPP 6224 Da, recIAPP 4918
Da, and recIAPP+C 7053 Da. Synthetic human IAPP used
in the study was synthesized by KEX Laboratories, Yale
University (New Haven, Conn, USA), and synthetic rat IAPP
was purchased from Bachem (Heidelberg, Germany).
2.6. Tricine-sodiumdodecylsulfate-polyacrylamide
gelelectrophoresis
Tricine-SDS-PAGE was performed as described by Sch¨ agger
and von Jagow [30]. Samples were dissolved in sample buﬀer
containing 0.1M Tris-HCl at pH 6.8, 30% (wt/vol) glycerol,
8% (wt/vol) SDS, 0.2M dithiothreitol (DTT), and 0.02%
Coomassie blue G-250 and boiled for 5 minutes prior to
loading onto the gel. The separation condition was 30mV
for 20 hours.
2.7. Silverstainingandtrypsindigestion
The tricine-SDS gel was sensitised in 1.4mM Na2S2O4
and incubated in 0.2% AgNO3 solution containing 7.5μL
formaldehyde (37%)/100mL water for 25 minutes and
developed in 6% Na2CO3,2 5 μMN a 2S2O3,a n d5 0 μL
formaldehyde (37%)/100mL water.
Silver stained bands corresponding to the expected
masses of the recombinant IAPP peptides were excised from
the gel and dried. Each sample was incubated with 60μL
reducing agent consisting of 10mM dithiothreitol (DTT) in
25mM NH4HC3 for one hour at +56
◦C, after which the
peptideswerealkylatedin70μL55mMiodoacetamide(IAA)
at room temperature in dark for 45 minutes. Rehydrated gel
pieces were digested in 100μL trypsin solution containing4 Experimental Diabetes Research
1.5μg/mL trypsin (Promega, Madison, Wis, USA) and
25mM NH4HCO3 and incubated 24 hours at +37
◦C.
2.8. Electrosprayionisationtandem
massspectrometry
Full scan mass spectra for peptide mass ﬁngerprinting
and TOF product scans for sequencing of amino acids
were acquired on a hybrid mass spectrometer (API QSTAR
Pulsar, Applied Biosystems, Foster city, Calif) equipped
with a nanoelectrospray ion source (MDS Protana, Odense,
Denmark).
2.9. Amyloidstaining
Samples were dried onto glass slides and incubated for 20
minutes in A solution (NaCl saturated 80% ethanol with
0.01% NaOH) and were directly transferred to B solution
(solution A saturated with Congo red). Samples were
rinsed in 100% ethanol and xylen and mounted. Amyloid
speciﬁc green birefringence was studied in an Olympus X51
microscope (Olympus, Tokyo, Japan) with two polarising
ﬁlters connected to an Olympus DP 50 digital camera run
by Studio Lite v 1.0.1 software.
2.10. Electronmicroscopy
Droplets of sample were placed on formvar coated copper
grids and were negative contrasted with 2% uranyl acetate in
50% ethanol. Samples were studied in a Jeol 1230 electron
microscope at 100kV (Jeol, Akishima, Tokyo, Japan). Digital
electron micrographs were taken with a Gatan multiscan
camera model 791 with corresponding software v3.6.4
(Gatan Inc, Pleasanton, Calif, USA).
2.11. ThioﬂavinTassay
Kinetic studies of amyloid formation were performed in
Sigmacote(Sigma-Aldrich,St.Louis,Mo,USA)treatedblack
96 well plates (Labsystems) in a sample volume of 100μL.
Synthetic IAPP was diluted from a DMSO stock solution
(5mM) to a ﬁnal concentration of 50μM in thioﬂavin
T (ThT) in assay buﬀe r( 5 0 m Mg l y c i n e ,2 5 m Ms o d i u m
phosphate buﬀer, pH 7.0, and 10μMT h T ) .M a t u r eI A P P
ﬁbrils (30nM) were included to decrease the amyloid lag
phase. Samples consisting of ThT assay buﬀer with 1%
DMSO and ThT assay buﬀer with 30nM IAPP ﬁbrils and
1% DMSO were included in the assay. Fluorescence was
measured every thirty minutes at an excitation wavelength of
442nm and an emission wavelength of 486nm. Each sample
was measured in 12 individual wells, and data presented are
mean values ± SEM.
2.12. Statisticalanalysis
S t a t i s t i c sw e r ep e r f o r m e di nG r a p h P a dI n S t a tv e r s i o n3 . 0 6
(GraphPad Software Inc., San Diego, Calif, USA). Unpaired
t-test was used when two groups were compared and one-
way analysis of variance (ANOVA) with Dunnett multiple
comparisons test when several groups were analysed. A P-
value less than 0.05 was considered signiﬁcant.
3. RESULTS
3.1. Evaluationofthemethod
Autoﬂuorescence from diﬀerent solutions was analysed at
emission wavelengths 535nm and 480nm (see Figure 1(a)).
The KRHG buﬀer had the lowest ﬂuorescence of the
investigated solutions and was therefore used as assay buﬀer
throughout the study.
To determine if the ﬂuorescent signal from the pFRET2-
DEVDtransfectedB-TC-6cellswassuﬃcientfordetectionin
the plate reader the signal was compared to the signal from
untransfectedB-TC-6cells.B-TC-6cellsexpressingpFRET2-
DEVD had a 6.5-fold higher ﬂuorescence signal at 535nm
and a 2.3-fold higher signal at 480nm when compared to the
untransfected B-TC-6 cells (see Figure 1(b)). Fluorescence
form transfected B-TC-6 cells diﬀered signiﬁcantly at both
wavelengths compared to untransfected B-TC-6 cells in an
unpaired t-test (P<. 0005). The 535nm/480nm ratio
for living pFRET2-DEVD transfected B-TC-6 cells was
2.2. Three hours incubation with the apoptosis inducer
staurosporine (2μM) decreased the FRET ratio to 1.2.
Synthetic human and rat IAPP peptides in monomeric
form, at concentrations 25 and 50μM, were incubated with
pFRET2-DEVD B-TC-6 cells. Only negligible reduction in
FRET signal was detected after 12 hour incubation, and cell
survival was calculated to 96% and 98% after incubation
with rat IAPP and human IAPP, respectively. There was no
diﬀerence between cells incubated with 25 or 50μM( d a t a
not shown). In the confocal microscope, the pFRET2-DEVD
B-TC-6 cells revealed a strong cytoplasmic ﬂuorescence at
excitation wavelength 488nm (see Figure 1(c)). This was not
present in untransfected cells (see Figure 1(d)).
3.2. AmyloidformationandlossofFRET
FRET reductionas aresultofamyloidformationwasinitially
investigated with synthetic IAPP peptides. The amyloid
formation from 50μM monomeric IAPP seeded with 30nM
IAPP ﬁbrils was monitored in the ThT assay and with the
FRET assay in parallel (see Figure 2). In the ThT assay, amy-
loid speciﬁc ﬂuorescence of seeded IAPP was detected after
a 3-hour lag phase and reached a plateau after 9 hours (see
Figure 2(a)). No increase in basal ﬂuorescence was detected
for the sample with ThT buﬀer alone or ThT buﬀer with
low concentration of premade IAPP seeds. To further study
the amyloid aggregation process, aliquots from the seeded
50μM IAPP solution were collected hourly and prepared
for electron microscopy. After 2 hours, small ring shaped
structures with an outer diameter of approximately 15nm
could be detected at high magniﬁcation (see Figure 2(b)).
After 4 hours of incubation, very thin thread-like ﬁbrils were
detected (see Figure 2(c)) and after 12 hours of incubation
ﬁbrils with a more mature ﬁbrillar appearance were visible
(see Figure 2(d)).Johan F. Paulsson et al. 5
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Figure 1: Determination of assay buﬀer and investigation of pFRET2-DEVD expressing B-TC-6 cells. (a) Solutions (KRHG, HBSS, RPMI
without FBS, RPMI, Dulbeccoc ¸s modiﬁed medium, Schneiderc ¸s drosophila medium, and H2O) were analysed for autoﬂuorescence at
wavelength 535nm (blue columns) and 480nm (red columns). Data presented are mean values ±SEM (n = 8). (b) Fluorescence at 535nm
and480nmwasmeasuredforKRHGbuﬀer(blackcolumns),B-TC-6cellsexpressingpFRET2-DEVD(greencolumns),anduntransfectedB-
TC-6 cells (grey columns). Data presented are mean values ±SEM (n = 8). Diﬀerence in ﬂuorescence signal between B-TC-6 cells expressing
pFRET2-DEVD and untransfected B-TC-6 was considered to be signiﬁcant (P<. 0005) in a two-tailed unpaired t-test. (c) Confocal image
of pFRET2-DEVD expressing B-TC-6 cells and (d) untransfected B-TC-6 cells. Argon 488nm and HeNe 633nm lasers were used at the
same energy levels in the two images. Green ﬂuorescence indicates expression of pFRET2-DEVD and blue ﬂuorescence nuclear staining
TO-PRO-3. Scale bars represent 10μm.
In the FRET measurements, pFRET2-DEVD expressing
B-TC-6 cells incubated with staurosporine used as positive
control showed an instant reduction of the 535nm/480nm
r a t i o .A f t e r4h o u r s ,t h er a t i ow a sr e d u c e dt o1 . 2( s e e
Figure 2(e)). The FRET ratio for pFRET2-DEVD expressing
B-TC-6 cells incubated with KRHG buﬀer and 30nM IAPP
seeds used as negative control were relative stable at a ratio
of 2.0 through out the assay. pFRET2-DEVD expressing B-
TC-6 cells incubated in 50μM IAPP peptide with 30nM
IAPP seeds showed a reduced FRET signal compared to the
negative control (see Figure 2(e)). The measurements were
done hourly for 12 hours, and the calculation was performed
as follows. The FRET ratio 535nm/480nm, determined
after 12 hours of incubation with the apoptosis-inducer
staurosporine, was set as baseline and corresponds to 0%
survivalcells.Allcellswereconsideredviableafterincubation
with preformed ﬁbrils, and the value for the FRET ratio
535nm/480nm was set as 100% after subtraction of the
baseline value.
The FRET ratio of the B-TC-6 cells incubated in amyloid
forming IAPP peptide corresponds to a population of 65%
apoptotic cells (see Figure 2(f)). B-TC-6 cells incubated
in amyloid forming IAPP diﬀered signiﬁcantly from the
negative control in a two-tailed unpaired t-test (P<. 006).
3.3. Characterisationofrecombinantpeptides
The recombinant peptides recproIAPP, recN+IAPP, recIAPP,
and recIAPP+C were expressed as fusion proteins and when
the GST-tag was enzymatically removed, all four peptides
formed aggregates during the 12 hours time period. The
aggregates from the diﬀerent recombinant peptides stained
withCongoredandrevealedgreenbirefringence(seeFigures
3(a)–3(d)). Negative contrasted aggregates showed typical
amyloid-like ﬁbrils with a diameter of 10nm and of variable
length (see Figures 3(e)–3(h)).
The expected amino acid sequences of recproIAPP,
recN+IAPP, recIAPP, and recIAPP+C was used to deter-
mine the expected molecular masses (see Figure 4(a)).The
produced peptides were run on Tricine SDS-PAGE and
bands corresponding to the molecular masses of each
individual peptide were cut out, trypsinised and analysed
by electrospray ionisation tandem mass spectrometry (see
Figure 4(b)). The expected tryptic fragments from each
peptide were identiﬁed in full scan spectrum (data not
shown), and the sequence of each fragment was conﬁrmed
by collision-induced fragmentation mass spectrometry. All
four IAPP peptides had a 10-amino acid residue sequence
consisting of residues GSRRASVGSP N-terminally which is a6 Experimental Diabetes Research
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Figure 2: Parallel performed ThT assay, electron microscopy, and FRET assay of synthetic IAPP peptide. (a) ThT assay of synthetic IAPP
peptide (50μM) seeded with preformed IAPP ﬁbrils (30nM) ( ), ThT assay buﬀer seeded with preformed IAPP ﬁbrils (30nm) ( ), and
ThT assay buﬀer ( ). Data presented are mean values ±SEM (n = 12). Synthetic IAPP peptide (50μM) seeded with preformed IAPP
ﬁbrils (30nM) incubated for (b) 2 hours of 50μM, (c) for 4 hours, (d) and for 12 hours; all samples were negative contrasted. In (b),
the higher magniﬁcation shows small preﬁbrillar ring shaped structures. In (c), thin thread-like protoﬁbrils are visible and in (d) more
mature amyloid-like ﬁbrils are apparent. Large-scale bars represent 100nm, and the smaller-scale bar in (b) represents 20nm. (e) FRET
ratio of 535nm/480nm measurements of KRHG buﬀer with seeds of preformed IAPP ﬁbrils (30nM) ( ), synthetic IAPP peptide (50μM)
seeded with preformed IAPP ﬁbrils (30nM) ( ), and staurosporine (2μM) ( ). Measurements were performed during a 12-hour period
with individual measurements each hour. Data presented are mean values ±SEM (n = 9). (f) FRET ratio after 12 hours of measurements.
Staurosporinesamplewassetaszeroandwassubtractedfromassaymeasurements,andthenegativecontrolwassetas100%viablecells(blue
column). The FRET ratio of the B-TC-6 cells incubated in synthetic IAPP peptide (50μM) seeded with preformed IAPP ﬁbrils (30nM) was
37% of the negative control corresponding to a population of 65% apoptotic cells (green column). Data presented are mean values ±SEM
(n = 9). The diﬀerence between the negative control and IAPP was considered signiﬁcant in a two-tailed unpaired t-test (P<. 0006).Johan F. Paulsson et al. 7
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Figure 3:Congoredstainingandelectronmicrographsofamyloid-likeﬁbrilsfromrecproIAPP,recN+IAPP,recIAPP,andrecIAPP+C.Congo
red staining viewed in polarised light showing amyloid speciﬁc green birefringence of (a) recproIAPP, (c) recN+IAPP, (e) recIAPP, and (g)
recIAPP+C. Scale bars represent 20μm. Electron micrographs of negative contrasted amyloid-like ﬁbrils of (b) recproIAPP, (d) recN+IAPP,
(f) recIAPP, and (h) recIAPP+C. Scale bars represent 100nm.
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Figure 4: Characterisation of recproIAPP, recN+IAPP, recIAPP, and recIAPP+C. (a) A cartoon showing the amino acid sequences of
recproIAPP, recN+IAPP, recIAPP, and recIAPP+C peptides. N-terminally, a fragment consisting of 10 residues originating from the GST-
tag is present (white box). (b) Silver stained tricine SDS-PAGE of recproIAPP, recN+IAPP, recIAPP, and recIAPP+C. Bands were removed
from the tricine gel, trypsinised and analysed by electrospray ionisation tandem mass spectrometry.8 Experimental Diabetes Research
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Figure 5: FRET assays of recproIAPP, recN+IAPP, recIAPP, and recIAPP+C. (a) B-TC-6 cells expressing pFRET2-DEVD were incubated with
solubilised recombinant peptides recproIAPP (50μM) ( ), recN+IAPP (50μM) ( ), recIAPP (50μM) ( ), and recIAPP+C (50μM) ( ),
all supplemented with preformed IAPP ﬁbrils at a concentration of 30nM or incubated with preformed IAPP ﬁbrils (30nM) alone ( ),
or staurosporine (2μM) ( ). The FRET ratio at 535/480nm was determined hourly over 12 hours. Data presented are mean value ±SEM
(n = 5). (b) Cell viability after incubation for 12 hours with solubilised recombinant peptides supplemented with preformed IAPP ﬁbrils
(30nM). Data are presented as mean value ±SEM (n = 5). Relative to the control, cell viability was determined to 51% for recproIAPP ( ),
54% for recN+IAPP ( ), 28% for recIAPP ( ), and 41% for recIAPP+C ( ). Compared to the control, a signiﬁcant diﬀerence in the FRET
ratio was observed for all four recombinant peptides in an ANOVA test (P<. 0005). (c) FRET ratio of pFRET2-DEVD expressing B-TC-6
cells after 12 hours of incubation with recombinant amyloid-like ﬁbrils corresponding to 50μM. RecproIAPP ( ), recN+IAPP ( ), recIAPP
( ), and recIAPP+C ( ) and control incubation with buﬀer alone ( ). Relative to the control, cell viability after incubation with recproIAPP
was 85%, with recN+IAPP 102%, with recIAPP 104% and with recIAPP+C 89%. No statistically diﬀerence between the negative control
and the four recombinant peptides was observed in an ANOVA test (P<. 5). (d) Incubation of pFRET2-DEVD expressing B-TC-6 cells
with recombinant peptides in solubilised form (50μM). RecproIAPP ( ), recN+IAPP ( ), recIAPP ( ), and recIAPP+C ( ) and control
incubation with buﬀer alone ( ). Relative to the control, cell viability after 12 hours incubation with recproIAPP was 86%, recN+IAPP 97%,
recIAPP 102%, and recIAPP+C 89%. The four recombinant peptides did not diﬀer signiﬁcantly from the negative control in an ANOVA test
(P>. 06).
rest from the GST cleavage site. These extra residues did not
interfere with the capability of the recombinant peptides to
form amyloid-like ﬁbrils as shown in Figure 3.
3.4. Apoptoticeffectofrecombinantpeptides
pFRET2-DEVD expressing B-TC-6 cells were incubated with
50μMo frecproIAPP, recN+IAPP, recIAPP, and recIAPP+C
together with 30nM IAPP seeds in KRHG buﬀer. A reduc-
tion of the FRET ratio was detected during the time laps of
the assay (see Figure 5(a)). After 12 hours of incubation, all
four recombinant peptides had generated a large reduction
of the FRET signal. The FRET ratio of the positive control
was set as zero and subtracted from all other measurements
and the negative control was set as 100% viable cells.
The FRET ratios for recproIAPP, recN+IAPP, recIAPP, and
recIAPP+C were 51%, 54%, 28%, and 41%, respectively,
when compared to the negative control. This corresponds
to a population of 49%, 46%, 72%, and 59% apoptotic cells
(see Figure 5(b)). All four groups diﬀered signiﬁcantly from
the negative control in an ANOVA test (P < .0005). No
signiﬁcant diﬀerence within the four recombinant peptide
g r o u p sw a sd e t e c t e di na nA N O V At e s t( P>. 2).
pFRET2-DEVD expressing B-TC-6 cells was also incu-
bated with mature amyloid-like ﬁbrils from recproIAPP,
recN+IAPP, recIAPP, and recIAPP+C. No diﬀerence in FRET
ratio was observed over time when compared to the negative
control (data not shown). After 12 hours of incubation,Johan F. Paulsson et al. 9
FRET ratios of recproIAPP, recN+IAPP, recIAPP, and
recIAPP+C were 85%, 102%, 104%, and 89%, respectively,
when the positive control was subtracted and the negative
control was set as 100% viable cells (see Figure 5(c)). No
signiﬁcant diﬀerences between the negative control and the
recombinant ﬁbrils and no diﬀerence between the four
diﬀerent peptides (P>. 5) were detected.
FRET measurements were also performed on pFRET2-
DEVD expressing B-TC-6 cells incubated with 50μMs o l u -
bilised and ﬁltered recombinant peptides. When compared
to the negative control, no loss of FRET was detected during
12 hours of measurements (data not shown). After 12 hours
of incubation and subtraction of the positive control, FRET
ratios for recproIAPP, recN+IAPP, recIAPP, and recIAPP+C
were 86%, 97%, 102%, and 89%, respectively, compared
to the negative control (see Figure 5(d)). No signiﬁcant
diﬀerence between the negative control and the monomeric
peptides and no diﬀerences between the four diﬀerent
recombinant peptides (P>. 06) were detected.
4. DISCUSSION
The pFRET2-DEVD vector has earlier been demonstrated
by K¨ ohler et al. to be an excellent reporter for apoptosis
induced by caspase-3-like proteases in the insulin producing
beta-cell lines RINm5F and MIN6 [29]. By measuring loss of
FRET on individual transiently transfected cells, the course
of apoptosis was monitored in real-time. Here, we used
the pFRET2-DEVD vector to establish a novel assay with
stable transfected B-TC-6 cells that allows accurate real-time
studies of apoptosis in 96 well plates. The assay was used for
studies of beta-cell apoptosis during amyloid formation, and
the toxicity of recproIAPP and the processing metabolites
recN+IAPP, recIAPP, and recIAPP+C is evaluated.
Initially, it was essential to ﬁnd an assay buﬀer with
very low autoﬂuorescence for measurement of FRET signal
from cells cultured in a black 96 well plate. The KRHG-
buﬀer revealed the lowest background and was selected
for the assay, but with the disadvantage of being a rather
poor medium. After 12 hours of FRET measurement, the
negative control started to show some reduction of FRET
and therefore measurements beyond this time point are
not presented throughout this work. The ﬂuorescent signal
detected from the pFRET2-DEVD transfected B-TC-6 cells
was adequate for plate reader measurements and since it is
the ratio between 535 and 480nm, that is, given diﬀerences
in cell density can be ignored. Synthetic IAPP peptide was
initially used for the setup of the method.
One step in the evaluation procedure of the FRET
method was to determine the amyloid ﬁbril formation
progressundertheusedpeptideconcentrationsandcorrelate
it to the induction of apoptosis. For this, a ThT assay
was run in parallel with identical IAPP concentrations.
When monomeric IAPP was seeded with preformed IAPP
amyloid-like ﬁbrils, an increase in ThT-ﬂuorescence signal
appearedafterathreehourslagphaseandreachedmaximum
after nine hours of incubation. Fibril formation could only
be detected in seeded IAPP samples, and not in samples
with seed alone. In samples collected for morphological
evaluation, an amorphous material was present after two
hours and at higher resolution ring-like structures with an
outer diameter of 15nm could be seen. After four hours
of incubation, thin slender ﬁbrils were present. Since no
ﬁbrilar material was present at the earlier time points we
conclude that these thin ﬁbrils were newly formed and did
not represent the low amount of sonicated preformed ﬁbrils
added as seed. In samples taken after 12 hours, ﬁbrils with a
more distinct ﬁbrilar appearance had emerged. The decrease
in FRET ratio after incubation with 2μM staurosporine
starts under the ﬁrst hour and continues over a ﬁve-hour
period. Staurosporine is a potent inducer of apoptosis, a
transientbiologicalprocessthatpersistsfor3-4hours.Inthis
positive control, all cells undergo apoptosis. In transfected
cells incubated with monomeric IAPP and preformed ﬁbrils,
apoptosis was initiated after approximately seven hours and
this is in line with the expected time frame if oligomers are
responsible for the induction of apoptosis.
The B-TC-6 cell line is of mouse origin, and it has
previously been suggested that mouse IAPP has an anti-
amyloidogenic eﬀect on human IAPP at least intracellularly
[31]. In vitro studies show that insulin also has an inhibitory
property on amyloid formation of human IAPP [32, 33].
Prior to the experimental procedure, the B-TC-6 cells
were washed in KRHG buﬀer which has a low glucose
concentration (2mM). Therefore, exocytosis of mouse IAPP
and insulin was considered to be very low during the assay
and not to inﬂuence the amyloidogenicity of human IAPP.
The predominant hypothesis of amyloid cytotoxicity
is that the preﬁbrillar assemblies are able to incorporate
into cellular membranes causing cation inﬂux [10, 34, 35].
Oligomeric species from diﬀerent peptides would there
share a common structure and act cytotoxic by the same
mechanisms. A common pathway for apoptosis triggered
by amyloid pore formation has not yet been proposed.
Apoptosis is the major cause of beta-cell reduction in type
2 diabetic patients and has been shown to occur during
formation of islet amyloid in a transgenic mouse model
[15, 36]. Two apoptosis studies on beta-cell lines have been
performed where activation of the caspase cascade in parallel
to IAPP amyloid formation has been observed [19, 20].
Both authors have used RINm5F cells and Zhang el al.
have also used the human insulinoma cell line CM. Both
groups reported the activation of the common downstream
protease caspase 3 with upstream activated JNK pathway
(c-jun NH2-terminal kinase/stress-activated protein kinase).
Zhang et al. also reported activated caspase 8 and caspase
1 proteases upstream of caspase 3. The exact pathways of
IAPP triggered apoptosis are not clear but caspase 3 acts
as a common downstream eﬀector. Zhang et al. state that
caspase 3 activation was detected after 8 hours of incubation
withpreseededsyntheticIAPPandreachedamaximumafter
16 hours [20]. No measurements between these time points
were performed. Our observation of the reduced FRET
signal goes well with these data, and upstream activation
must occur before we detect FRET reduction by caspase 3
activation.
All four recombinant peptides, recproIAPP, recN+IAPP,
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and form ﬁbrillar aggregates. The extra amino acid residues
N-terminally of the recombinant peptides do not interfere
with the amyloidogenic propensity since all four peptides
form amyloid-like ﬁbrils. The apoptotic eﬀects of the
recombinant peptides were investigated using the developed
FRET assay. The recombinant peptides were studied in
solubilised seeded, ﬁbrillar, and in solubilised nonseeded
form. A loss of FRET was detected for all four seeded
solubilised recombinant peptides. At the end of the assay,
an apoptotic rate ranging form 46–72% was observed for
the four diﬀerent seeded recombinant peptides though no
statistically signiﬁcant diﬀerence between the groups was
distinguished. Important, the degree of apoptosis did not
diﬀer between cells incubated with synthetic IAPP (65%) or
recIAPP (72%) (P>. 5) pointing out that the addition of the
10 residues at the N-terminus of the recombinant IAPP did
not interfere with the cytotoxicity of the peptide.
B-TC-6 cells expressing pFRET2-DEVD were incubated
with mature amyloid ﬁbrils from recproIAPP, recN+IAPP,
recIAPP, and recIAPP+C and no apoptosis was detected.
Since the amyloid-like ﬁbrils were extensively washed with
water, a pure ﬁbril fraction without any oligomeric species
would be expected. Solubilised nonseeded recombinant
peptides did not elicit a reduction of the FRET signal, most
likely due to a long lag phase. From this we conclude that
thecytotoxicspeciesofsyntheticandrecombinantamyloido-
genic IAPP peptides are early oligomers or protoﬁbrils. This
is in consensus with earlier studies [16, 17, 37].
A new and very interesting ﬁnding is that recproIAPP
andtheprocessingintermediatesrecN+IAPPandrecIAPP+C
trigger beta-cell apoptosis. Earlier we and others have shown
that islet amyloid deposition may start intracellularly and
that aberrant processing of proIAPP can be an initiating
event [26, 27]. Intracellular deposits containing proIAPP
have been found both in transgenic mice expressing human
IAPP and in human beta-cells transplanted under the renal
capsule of mice fed a high fat diet [28]. In the latter study, we
also found intra-granular amyloid-like ﬁbrils consisting of
proIAPP. It has previously been shown that amyloid forma-
tion of IAPP was strongly enhanced by phospholipid bilayers
and that amyloid elongation occurred from the surface of
the lipid bilayer [38]. Hypothetically, the membrane of the
secretory granule or endoplasmatic reticulum may be the
location of initial amyloid formation and where oligomeric
pore structures can incorporate. By exocytosis, the granule
membrane will fuse with the outer cell membrane and a
cation inﬂux and activation of apoptotic pathways might
occur. Here, we demonstrate that recproIAPP and the
processing intermediates recN+IAPP and recIAPP+C can
induce caspase 3 activation and trigger beta-cell apoptosis.
This is achieved by preﬁbrillar toxic species since ﬁbrillar
and monomeric forms of the recombinant peptides did not
trigger caspase 3-like activity. This further strengthens our
hypothesis that aberrant processing of proIAPP plays a key
role in early islet amyloidogenesis.
Apoptosis is a transient event, and the established assay
allows analysis over time of the same cell population.
It is a system with high reproducibility, and it is cost
eﬀective and easy to handle. Apoptosis assays where Ac-
DEVD-AMC is used as ﬂuorogenic substrate is often labour
intense and the commonly used MTT assay, where only
living cells are measured, is not a true assay for apoptosis.
The Vybrant apoptosis detection kit uses three diﬀerent
ﬂuorescent nuclear stains with the propensity to penetrate
cell membrane according to an apoptotic or nonapoptotic
state. This method is performed on living cells and must be
analysed microscopically. It is work intense and dependent
on the interpretation of the analyst. Also TUNEL and DNA
fragmentation methods are labour intense and similar to all
the methods described above, only measurement at one time
point is possible. Factors such as equal amounts of cells in
each well or assay and rate of cell division are very important
to consider when to deal with the described methods. The
weakness of our FRET assay is the poor medium in which
the assay is performed. Further investigations of possible
media to prolong the survival of the cells and thereby
allow measurements over a more extended period of time
would be valuable. Future prospects for this method are to
study apoptosis in presence of antiamyloidogenic or amyloid
enhancing factors depending on strategy to reduce toxic
species in the amyloid forming process.
ABBREVIATIONS
DMSO: Dimethyl sulfoxide
ECFP: Enhanced cyan ﬂuorescent protein
E Y F P : E n h a n c e dy e l l o wﬂ u o r e s c e n tp r o t e i n
FBS: Fetal bovine serum
FRET: Fluorescence resonance energy transfer
GST: Glutathione S-transferase
HBSS: Hank’s balanced salt solution
IAPP: Islet amyloid polypeptide
IPTG: Isopropyl β-D-1 thiogalactopyranoside
KRHG: Krebs-Ringer salt solution with hepes and
glucose
PC: Prohormone convertase
recIAPP: Recombinant islet amyloid polypeptide
recIAPP+C: Recombinant islet amyloid polypeptide with
C-terminal ﬂanking peptide
recN+IAPP: Recombinant islet amyloid polypeptide with
N-terminal ﬂanking peptide
recproIAPP: Recombinant pro islet amyloid polypeptide
ThT: Thioﬂavin T
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